However, this enhanced activity was accompanied by severe treatment-related toxicities, particularly cytokine release syndrome (CRS), underscoring the need for optimized IL-15 regulation strategies, such as inducible or membrane-bound IL-15 expression, to balance therapeutic potency with safety (22, 23). This evidence concerns the gene IL15 and congenital rubella syndrome.